In addition, the Phase III FLAURA trial demonstrated osimertinib’s superiority to the standard of care TKI with CNS ORR 66% versus 43% in EGFR-mutated treatment naïve NSCLC patients [26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.